Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | CYP4F2 | P78329 | 3/20 | 0.38 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.38 |
| ▸ | RXRA | P19793 | 1/20 | 0.38 |
| ▸ | RXRB | P28702 | 1/20 | 0.38 |
| ▸ | RXRG | P48443 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 4/20 | 0.36 |
| ▸ | MAPT | P10636 | 4/20 | 0.36 |
| ▸ | RAB9A | P51151 | 4/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.36 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.36 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MITF | O75030 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12957073 | 0.85 | ALDH1A1 (0.46) | ALDH1A1POLBLMNASMN1; SMN2KMT2A | |
| SCHEMBL8242935 | 0.82 | ALDH1A1 (0.43) | ALDH1A1POLBLMNASMN1; SMN2KMT2A | |
| SCHEMBL31641559 | 0.81 | ALDH1A1 (0.47) | ALDH1A1POLBLMNASMN1; SMN2KMT2A | |
| SCHEMBL14903852 | 0.80 | CYP4F2 (0.47) | ALDH1A1POLBLMNASMN1; SMN2KMT2A | |
| SCHEMBL30045758 | 0.80 | ALDH1A1 (0.52) | ALDH1A1POLBLMNASMN1; SMN2KMT2A | |
| SCHEMBL3717759 | 0.80 | CYP4F2 (0.44) | ALDH1A1POLBLMNASMN1; SMN2KMT2A | |
| SCHEMBL26964696 | 0.79 | ALDH1A1 (0.43) | ALDH1A1POLBLMNASMN1; SMN2KMT2A | |
| SCHEMBL17063260 | 0.77 | ALDH1A1 (0.43) | ALDH1A1POLBLMNASMN1; SMN2KMT2A | |
| SCHEMBL1674135 | 0.77 | ALDH1A1 (0.43) | ALDH1A1POLBLMNASMN1; SMN2KMT2A | |
| SCHEMBL1475947 | 0.77 | ALDH1A1 (0.43) | ALDH1A1POLBLMNASMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12435078-B2 | Pyridazinones and methods of use thereof | GFB (ABC), LLC (US) | 2025-10-07 | — | — | US | disclosed |
| US-12202818-B2 | Compounds and methods for CD73 modulation and indications therefor | Opna Bio SA (CH) | 2025-01-21 | — | — | US | disclosed |
| EP-4139296-B1 | COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR | Opna Bio SA (CH) | 2024-09-18 | — | — | EP | disclosed |
| US-20240174640-A1 | COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR | Opna Bio SA (CH) | 2024-05-30 | — | — | US | disclosed |
| US-11807626-B2 | Compounds and methods for CD73 modulation and indications therefor | Opna Bio SA (CH) | 2023-11-07 | — | — | US | disclosed |
| US-11807626-B2 | Compounds and methods for CD73 modulation and indications therefor | Opna Bio SA (CH) | 2023-11-07 | — | — | US | disclosed |
| US-11807626-B2 | Compounds and methods for CD73 modulation and indications therefor | Opna Bio SA (CH) | 2023-11-07 | — | — | US | disclosed |
| CN-116731013-A | Heterocyclic compound, preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2023-09-12 | — | — | CN | disclosed |
| US-20230203028-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GFB (ABC), LLC | 2023-06-29 | — | — | US | disclosed |
| US-20230203028-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GFB (ABC), LLC | 2023-06-29 | — | — | US | disclosed |
| WO-2010131147-A1 | CYCLOBUTENEDIONE DERIVATIVES | PFIZER LIMITED (GB) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010131147-A1 | CYCLOBUTENEDIONE DERIVATIVES | PFIZER LIMITED (GB) | 2010-11-18 | — | — | WO | disclosed |
| US-20100286390-A1 | PYRIDAZINONE COMPOUNDS AND P2X7 RECEPTOR INHIBITORS | NISSAN CHEMICAL INDUSTRIES LIMITED | 2010-11-11 | — | — | US | disclosed |
| US-7598259-B2 | mGluR1 antagonists as therapeutic agents | SCHERING CORPORATION (US) | 2009-10-06 | — | — | US | disclosed |
| US-7598259-B2 | mGluR1 antagonists as therapeutic agents | SCHERING CORPORATION (US) | 2009-10-06 | — | — | US | disclosed |
| US-20090192178-A1 | mGluR1 ANTAGONISTS AS THERAPEUTIC AGENTS | SCHERING CORPORATION | 2009-07-30 | — | — | US | disclosed |
| US-20090192178-A1 | mGluR1 ANTAGONISTS AS THERAPEUTIC AGENTS | SCHERING CORPORATION | 2009-07-30 | — | — | US | disclosed |
| WO-2007070393-A2 | MGLUR1 ANATGONISTS AS THERAPEUTIC AGENTS | SCHERING CORPORATION (US) | 2007-06-21 | — | — | WO | disclosed |
| US-20060167029-A1 | mGluR1 Antagonists as therapeutic agents | SCHERING CORPORATION | 2006-07-27 | — | — | US | disclosed |
| US-20060167029-A1 | mGluR1 Antagonists as therapeutic agents | SCHERING CORPORATION | 2006-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203028-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | PDXK, ATP6V1B1, REN | ALDH1A1 649/4885POLB 1701/4885LMNA 715/4885 |
| US-12202818-B2 | Compounds and methods for CD73 modulation and indications therefor | ENTPD5, ENTPD1, ADORA2A | ALDH1A1 208/4885POLB 1748/4885LMNA 1207/4885 |
| US-20240174640-A1 | COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR | ENTPD5, ENTPD1, ADORA2A | ALDH1A1 208/4885POLB 1748/4885LMNA 1207/4885 |
| US-20090192178-A1 | mGluR1 ANTAGONISTS AS THERAPEUTIC AGENTS | GRM1, GRM4, GRIA1 | ALDH1A1 1026/4885POLB 3959/4885LMNA 4462/4885 |
| US-20100286390-A1 | PYRIDAZINONE COMPOUNDS AND P2X7 RECEPTOR INHIBITORS | P2RY1, P2RX7, P2RX1 | ALDH1A1 2584/4885POLB 3633/4885LMNA 1782/4885 |
| US-20060167029-A1 | mGluR1 Antagonists as therapeutic agents | GRM1, GRM4, GRIA1 | ALDH1A1 1026/4885POLB 3959/4885LMNA 4462/4885 |
| US-12435078-B2 | Pyridazinones and methods of use thereof | PDXK, ATP6V1B1, REN | ALDH1A1 649/4885POLB 1701/4885LMNA 715/4885 |
| US-11807626-B2 | Compounds and methods for CD73 modulation and indications therefor | ENTPD5, ENTPD1, ADORA2A | ALDH1A1 208/4885POLB 1748/4885LMNA 1207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.